Cargando…

Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy

Detalles Bibliográficos
Autores principales:	Coelingh Bennink, Herjan J.T., Foidart, Jean-Michel, Debruyne, Frans M.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association of Urology. Published by Elsevier B.V. 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257425/ https://www.ncbi.nlm.nih.gov/pubmed/34274135 http://dx.doi.org/10.1016/j.eururo.2021.06.024

Ejemplares similares

Reply to Bexultan Kazybay and Yingqiu Xie’s Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Testosterone suppression combined with high dose estrogen as potential treatment of SARS-CoV-2. A mini review
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2022)

Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives
por: Mawet, Marie, et al.
Publicado: (2015)

A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life
por: Gaspard, Ulysse, et al.
Publicado: (2023)

Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer
por: Schmidt, Marcus, et al.
Publicado: (2020)

A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety
por: Gaspard, Ulysse, et al.
Publicado: (2020)

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study
por: Duijkers, Ingrid J.M., et al.
Publicado: (2015)

Target expression is a relevant factor in synthetic lethal screens
por: Schultz, Iman J., et al.
Publicado: (2022)

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
por: Coelingh Bennink, Herjan J T, et al.
Publicado: (2022)

Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells
por: Yue, Wei, et al.
Publicado: (2019)

Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
por: Zimmerman, Yvette, et al.
Publicado: (2022)

Hormonal therapies and venous thrombosis: Estrogen matters!
por: Morimont, Laure, et al.
Publicado: (2023)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024
por: Kazybay, Bexultan, et al.
Publicado: (2021)

The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis
por: Zimmerman, Y., et al.
Publicado: (2014)

“The pill” suppresses adolescent bone growth, no matter the estrogen dose
por: Brajic, Tatjana S., et al.
Publicado: (2021)

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy
por: Douxfils, Jonathan, et al.
Publicado: (2023)

Hormonal therapies and venous thrombosis: considerations for prevention and management—a reappraisal
por: Douxfils, Jonathan, et al.
Publicado: (2023)

Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women
por: Cunha, Flávia Siqueira, et al.
Publicado: (2018)

Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study
por: Tskitishvili, Ekaterine, et al.
Publicado: (2016)

The chicken or the egg: low testosterone predisposes for COVID-19 or COVID-19 induces a decrease in testosterone?
por: Stolk, Roeland F., et al.
Publicado: (2021)

Associations of Estrogen and Testosterone With Insulin Resistance in Pre- and Postmenopausal Women With and Without Hormone Therapy
por: Matsui, Sumika, et al.
Publicado: (2013)

Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview
por: Archer, David F., et al.
Publicado: (2022)

Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms
por: Gérard, Céline, et al.
Publicado: (2015)

Competition Seriousness and Competition Level Modulate Testosterone and Cortisol Responses in Soccer Players
por: Jiménez, Manuel, et al.
Publicado: (2020)

Progesterone from ovulatory menstrual cycles is an important cause of breast cancer
por: Coelingh Bennink, Herjan J. T., et al.
Publicado: (2023)

The first synthetic estrogen.
por: Ashby, J
Publicado: (1998)

SUN-LB001 Estetrol (E4) Is a Unique Estrogen with Selective Actions in Tissues Which Are Distinctly Different from the Actions of SERMs
por: Foidart, Jean-Michel, et al.
Publicado: (2019)

Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia
por: Prince, Marloe, et al.
Publicado: (2016)

Testosterone in COVID-19: Friend or Foe?
por: Niemann, Peter J., et al.
Publicado: (2021)

Procedural Characteristics and Medications to Prevent Sinus Node Artery Occlusion During Cardioneuroablation
por: Debruyne, Philippe
Publicado: (2022)

Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer
por: Morgentaler, Abraham, et al.
Publicado: (2020)

Letter to the Editor on “COVID-19 Infection in Men on Testosterone Replacement Therapy”
por: MacDonald, Scott, et al.
Publicado: (2021)

Testosterone Replacement Therapy
por: Hellstrom, Wayne J.G.
Publicado: (2004)

SAT-052 A Novel Oral Testosterone Therapy (TLANDO) Safely Restores Testosterone to Eugonadal Levels with Fixed Dose Treatment
por: DelConte, Anthony, et al.
Publicado: (2020)

Environmental estrogens.
por: Wolff, M S
Publicado: (1995)

Alachlor not estrogenic.
por: Heydens, W F, et al.
Publicado: (1994)

Estrogenicity of styrene oligomers and assessment of estrogen receptor binding assays.
por: Ohno, Katsutoshi, et al.
Publicado: (2002)

Arrhythmogenic substrate elimination for safe testosterone therapy in symptomatic Brugada syndrome patients
por: Negro, Gabriele, et al.
Publicado: (2023)

Letter to the Editor regarding ‘Treatment of Men for “Low Testosterone”: A Systematic Review’ by Huo et al.; Testosterone Replacement Therapy: Toward to the Robust Evidence and Facts
por: Jung, Jae Hung, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a0lgam01k0jeqpvj08ame3td3d